Clinical trialNCT07459673RecruitingPhase 2Interventional

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

SponsorMemorial Sloan Kettering Cancer CenterEnrollment60Breast CancerBreast Cancer Stage IVHER2-positive Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Thie purpose of this study is to find out whether a personalized treatment approach-using a series of ctDNA tests along with standard imaging scans to help decide when to step up (escalate) or decrease (de-escalate) sequential treatments (given one after another)-combined with local therapies (which treat cancer in a specific part of the body) and treatments that prevent cancer from spreading to the central nervous system (CNS; including the brain and spinal cord) can result in long-lasting remission and possibly cure some participants with HER2+ metastatic breast cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering at Basking Ridge (limited Protocol Activities)
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering at Monmouth (limited Protocol Activities)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering at Bergen (limited Protocol Activities)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Suffolk-Commack (limited Protocol Activities)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering at Westchester (limited Protocol Activities)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activites)
New York, New York, United States
Recruiting
Memorial Sloan Kettering at Nassau (limited Protocol Activities)
Uniondale, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Trastuzumab →Pertuzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 Mar 2026
Primary completion: 4 Mar 2030
Completion: 4 Mar 2030
Last update posted: 20 Aug 2026
Registered enrollment: 60
Registry id: NCT07459673

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.